Levi & Korsinsky Reminds Shareholders Of A Lead Plaintiff Deadline Of November 5, 2024 In Agenus Lawsuit - Agen

NEW YORK, NY / ACCESSWIRE / September 18, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=103676&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Agenus Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the combination therapy of their immuno-oncology products, botensilimab and balstilimab was less effective than the defendants had led investors to believe; (ii) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Agenus stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=103676&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $50,000 in Agenus (https://api.newsfilecorp.com/redirect/X3m13sRAO4) between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information] (https://api.newsfilecorp.com/redirect/DZPaZfM7Zq)

New York, New York--(Newsfile Corp. - September 18, 2024) - Faruqi & Faruqi, LLP (https://api.newsfilecorp.com/redirect/rvQxvTxBPN), a leading national securities law firm, is investigating potential claims against Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) and reminds investors of the November 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

(https://images.newsfilecorp.com/files/6455/223654_62cbe9d364385a5c_001...)

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; (2) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

On July 18, 2024, Agenus issued a press release announcing the results of an "end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab and balstilimab, for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases." The press release revealed that the "FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to survival benefit."

On this news, Agenus's stock price fell $10.43 per share, or 58.83%, to close at $7.30 per share on July 18, 2024.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Agenus' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Agenus class action, go to www.faruqilaw.com/AGEN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn (https://api.newsfilecorp.com/redirect/4QrbQCzDbV), on X (https://api.newsfilecorp.com/redirect/jprnpfJ4oM), or on Facebook (https://api.newsfilecorp.com/redirect/v15n1fY7Eg).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223654

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).

Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=103181&from=3

CLASS PERIOD: January 23, 2023 to July 17, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the combination therapy of their immuno-oncology products, botensilimab and balstilimab was less effective than the defendants had led investors to believe; (ii) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

DEADLINE: November 5, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=103181&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of AGEN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 5, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

NEW YORK, NY / ACCESSWIRE / September 18, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=103569&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Agenus Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the combination therapy of their immuno-oncology products, botensilimab and balstilimab was less effective than the defendants had led investors to believe; (ii) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in Agenus stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=103569&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171https://zlk.com/

SOURCE: Levi & Korsinsky, LLP